Activist investor Bill Ackman’s Pershing Square has reported a return of -2.3% in the first quarter of 2017 – the first public glimpse of its performance since its London Stock Exchange debut earlier this month.

The negative performance for Ackman's hedge fund follows a major loss for the investor in March when he finally sold his stake in struggling drugmaker Valeant Pharmaceuticals, shouldering an approximately $4 billion loss.